Oas1e, an interferon (IFN)-inducible protein, plays a significant role in cellular responses to viral infections. Its activity is intricately linked to the IFN signaling pathway and can be modulated by compounds that influence this pathway. Epigallocatechin Gallate (EGCG) and Curcumin, for instance, exert their effects on Oas1e by modulating the NF-κB and JAK/STAT pathways, respectively. EGCG activates NF-κB, a pivotal factor in enhancing IFN-induced gene expression, thereby indirectly boosting Oas1e activity. Curcumin, on the other hand, activates the JAK/STAT pathway, crucial for IFN signal transduction, thereby facilitating Oas1e's functional upregulation. Similarly, Resveratrol and Sulforaphane enhance Oas1e activity through SIRT1 and Nrf2 pathways, respectively, both of which augment IFN signaling. This enhancement of IFN signaling, in turn, promotes the activity of Oas1e. Additionally, TPCA-1 and Piperlongumine influence Oas1e indirectly; TPCA-1 by modulating NF-κB activity through IKK-2 inhibition and Piperlongumine by increasing ROS levels, affecting NF-κB and STAT pathways.
The activity of Oas1e is also modulated by compounds that indirectly influence the IFN signaling pathway through various mechanisms. JQ1, a BET bromodomain inhibitor, enhances IFN signaling by inhibiting negative regulators, thereby indirectly increasing Oas1e activity. Quercetin and Ruxolitinib play roles in modulating the STAT component of the JAK/STAT pathway, with Quercetin enhancing STAT1 activity and Ruxolitinib paradoxically increasing cell sensitivity to IFN signals. Stattic's selective inhibition of STAT3 leads to a compensatory upregulation of STAT1, enhancing IFN signaling and thus Oas1e activity. Furthermore, Palbociclib and Andrographolide indirectly augment Oas1e activity; Palbociclib by affecting cell cycle-related signals that intersect with IFN signaling, and Andrographolide by activating transcription factors within the IFN pathway. Collectively, these compounds enhance Oas1e's role in the IFN signaling pathway, demonstrating a diverse yet interconnected network of biochemical pathways that converge to regulate this crucial protein.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Activates NF-κB signaling, indirectly enhancing Oas1e by upregulating IFN-inducible genes. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor that indirectly enhances Oas1e by inhibiting negative regulators of IFN pathway. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates SIRT1, positively regulating the IFN signaling pathway and indirectly promoting Oas1e activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Activates the JAK/STAT pathway, indirectly increasing Oas1e activity through enhanced IFN signaling. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
An IKK-2 inhibitor that modulates NF-κB activity, indirectly enhancing IFN signaling and upregulating Oas1e. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Activates Nrf2, indirectly promoting Oas1e activity by upregulating IFN-stimulated genes. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Enhances STAT1 activity in the JAK/STAT pathway, promoting Oas1e function through increased IFN signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor that paradoxically enhances cell sensitivity to IFN signals, indirectly enhancing Oas1e activity. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Selectively inhibits STAT3, leading to compensatory upregulation of STAT1 and enhanced IFN signaling, indirectly upregulating Oas1e. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that indirectly enhances Oas1e activity by modulating cell cycle-related signals intersecting with IFN signaling pathways. | ||||||